JP2022534510A5 - - Google Patents
Info
- Publication number
- JP2022534510A5 JP2022534510A5 JP2021570725A JP2021570725A JP2022534510A5 JP 2022534510 A5 JP2022534510 A5 JP 2022534510A5 JP 2021570725 A JP2021570725 A JP 2021570725A JP 2021570725 A JP2021570725 A JP 2021570725A JP 2022534510 A5 JP2022534510 A5 JP 2022534510A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- solid
- dosage forms
- intracisionally
- intravesically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911021098 | 2019-05-28 | ||
| IN201911021098 | 2019-05-28 | ||
| PCT/IN2020/050471 WO2020240586A1 (en) | 2019-05-28 | 2020-05-26 | Novel compounds for inhibition of janus kinase 1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534510A JP2022534510A (ja) | 2022-08-01 |
| JP2022534510A5 true JP2022534510A5 (https=) | 2024-07-16 |
| JP7592029B2 JP7592029B2 (ja) | 2024-11-29 |
Family
ID=73553608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570725A Active JP7592029B2 (ja) | 2019-05-28 | 2020-05-26 | ヤヌスキナーゼ１の阻害のための新規化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12516056B2 (https=) |
| EP (1) | EP3976612A4 (https=) |
| JP (1) | JP7592029B2 (https=) |
| CN (1) | CN114174294B (https=) |
| AU (1) | AU2020284742B2 (https=) |
| BR (1) | BR112021023635A2 (https=) |
| CA (1) | CA3141571A1 (https=) |
| MX (1) | MX2021014361A (https=) |
| TW (1) | TWI839524B (https=) |
| WO (1) | WO2020240586A1 (https=) |
| ZA (1) | ZA202109183B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023526521A (ja) * | 2020-05-21 | 2023-06-21 | ステムシナジー セラピューティクス， インク． | Ｎｏｔｃｈ阻害剤及びそれらの使用 |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| PE20250019A1 (es) * | 2021-05-06 | 2025-01-07 | Exscientia Ai Ltd | MODULADORES DE PKC-theta |
| WO2022234298A1 (en) * | 2021-05-06 | 2022-11-10 | Exscientia Ai Limited | Pkc-theta modulators |
| EP4452944A1 (en) * | 2021-12-22 | 2024-10-30 | Icagen, LLC | Cyclopropyl compounds |
| CN117050074B (zh) * | 2022-05-05 | 2025-08-12 | 中国药科大学 | 一类吡啶联咪唑并吡啶化合物及其制备方法与用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5002851B2 (ja) * | 2005-01-20 | 2012-08-15 | 独立行政法人理化学研究所 | イミダゾピリジン誘導体 |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| UY29825A1 (es) | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| SG10202003901UA (en) * | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| EP2244711A4 (en) * | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| US20110201599A1 (en) * | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| FI124118B (fi) * | 2011-06-13 | 2014-03-31 | Reijo Uolevi Hautalahti | Aurinkoenergian avulla sähköä ja lämpöä tuottava voimala |
| KR20130076046A (ko) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
| ES2567552T3 (es) * | 2012-01-30 | 2016-04-25 | Cephalon, Inc. | Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos |
| CN104140426B (zh) * | 2013-05-07 | 2017-02-01 | 上海汇伦生命科技有限公司 | 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途 |
| US10253023B2 (en) | 2014-10-06 | 2019-04-09 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| CN105837572B (zh) | 2015-02-02 | 2019-04-19 | 四川大学 | N-取代苯基酰胺衍生物及其制备方法和用途 |
| CN106146504B (zh) * | 2015-04-17 | 2018-09-07 | 上海汇伦生命科技有限公司 | 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途 |
| ES2830446T3 (es) | 2015-12-11 | 2021-06-03 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Derivado de azetidina, método de preparación del mismo y uso del mismo |
| CN109641892B (zh) * | 2016-08-16 | 2021-07-02 | 默克专利有限公司 | 用作可逆btk抑制剂的2-氧代-咪唑并吡啶及其用途 |
| GB201717260D0 (en) | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| CN113508114B (zh) * | 2019-02-27 | 2024-03-26 | 四川科伦博泰生物医药股份有限公司 | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 |
-
2020
- 2020-05-26 AU AU2020284742A patent/AU2020284742B2/en active Active
- 2020-05-26 CA CA3141571A patent/CA3141571A1/en active Pending
- 2020-05-26 EP EP20812987.4A patent/EP3976612A4/en active Pending
- 2020-05-26 WO PCT/IN2020/050471 patent/WO2020240586A1/en not_active Ceased
- 2020-05-26 US US17/614,114 patent/US12516056B2/en active Active
- 2020-05-26 BR BR112021023635A patent/BR112021023635A2/pt unknown
- 2020-05-26 MX MX2021014361A patent/MX2021014361A/es unknown
- 2020-05-26 CN CN202080054241.8A patent/CN114174294B/zh active Active
- 2020-05-26 JP JP2021570725A patent/JP7592029B2/ja active Active
- 2020-05-27 TW TW109117600A patent/TWI839524B/zh active
-
2021
- 2021-11-17 ZA ZA2021/09183A patent/ZA202109183B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534510A5 (https=) | ||
| JP5769762B2 (ja) | 治療組成物およびその使用 | |
| JP2016065086A5 (https=) | ||
| JP4832045B2 (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| JP2018534348A5 (https=) | ||
| JP2022537551A5 (https=) | ||
| JP2015510916A5 (https=) | ||
| JP2026009323A (ja) | 医薬品 | |
| JP2010524882A5 (https=) | ||
| US20180169067A1 (en) | Combination drug therapies for cancer and methods of making and using them | |
| JP2018512451A5 (https=) | ||
| RU2002129873A (ru) | Применение олтипраза для профилактики и лечения фиброза и цирроза печени и фармацевтическая композиция, содержащая олтипраз | |
| JP2020530447A5 (https=) | ||
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP7274288B2 (ja) | 医薬品 | |
| JP2023071181A5 (https=) | ||
| CN101663035B (zh) | 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途 | |
| JP6179515B2 (ja) | 安定化された内服用固形製剤 | |
| CN104173303B (zh) | 一种含有利奈唑胺的组合物及其制备方法 | |
| JP2000159674A (ja) | 解熱鎮痛消炎剤 | |
| FI3886857T3 (fi) | Montelukasti erosiivisen käden nivelrikon hoitoon | |
| JP6114573B2 (ja) | ロキソプロフェンナトリウムと制酸剤を含有する固形製剤 | |
| JP6838474B2 (ja) | 固形組成物 | |
| JP2017515858A5 (https=) | ||
| JP6149625B2 (ja) | 医薬組成物 |